Literature DB >> 8370580

Prosaposin deficiency: further characterization of the sphingolipid activator protein-deficient sibs. Multiple glycolipid elevations (including lactosylceramidosis), partial enzyme deficiencies and ultrastructure of the skin in this generalized sphingolipid storage disease.

V Bradová1, F Smíd, B Ulrich-Bott, W Roggendorf, B C Paton, K Harzer.   

Abstract

Sphingolipid activator protein (SAP) deficiency, previously described in two sibs and shown to be caused by the absence of the common saposin precursor (prosaposin), was further characterized by biochemical lipid and enzyme studies and by ultrastructural analysis. The 20-week-old fetal sib had increased concentrations of neutral glycolipids, including mono-, di-, tri- and tetrahexosylceramide, in liver, kidney and cultured skin fibroblasts compared with the controls. Glucosylceramide and lactosylceramide were particularly elevated. The kidney of the affected fetus showed additional increases in the concentration of sulphatide, galactosylceramide and digalactosylceramide. Free ceramide was stored in the liver and kidney, and GM3 and GM2 gangliosides were elevated in the liver, but not the brain, of the fetus. Phospholipids, however, were normal in the affected fetus. In the liver biopsy of the propositus, who later died at 16 weeks of age, only a few lipids could be studied. Glucosylceramide, dihexosylceramide and ceramide were elevated in agreement with our previous study. Enzyme studies were undertaken using detergent-free liposomal substrate preparations and fibroblast extracts. The sibs' beta-glucocerebrosidase and beta-galactocerebrosidase activities were clearly reduced, but their sphingomyelinase activities were normal. The normal activity of the latter enzyme and the almost normal tissue concentration of sphingomyelin in prosaposin deficiency suggest that the prosaposin-derived SAPs are not required for sphingomyelinase activity in vivo. In keeping with the biochemical findings, skin biopsies from the sibs showed massive lysosomal storage with a vesicular and membranous ultrastructure. The function of SAPs in sphingolipid degradation and the role of SAPs for enzyme activity in vitro are discussed. In addition, the similarity in neutral glycolipid accumulations in Niemann-Pick disease type C and in prosaposin deficiency are noted. The phenotype of the prosaposin deficient sibs resembled acute neuronopathic (type 2) Gaucher disease more than Farber disease in several aspects, but their genotype was unique.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8370580     DOI: 10.1007/bf00219682

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  39 in total

1.  Improved one-dimensional thin-layer chromatography for the separation of phospholipids in biological material.

Authors:  V Bradová; F Smid; J Ledvinová; C Michalec
Journal:  J Chromatogr       Date:  1990-11-30

2.  Metabolism of galactosylceramide in the twitcher mouse, an animal model of human globoid cell leukodystrophy.

Authors:  T Kobayashi; N Shinnoh; Y Kuroiwa
Journal:  Biochim Biophys Acta       Date:  1986-11-14

Review 3.  Type C Niemann-Pick disease: biochemical aspects and phenotypic heterogeneity.

Authors:  M T Vanier; C Rodriguez-Lafrasse; R Rousson; S Duthel; K Harzer; P G Pentchev; A Revol; P Louisot
Journal:  Dev Neurosci       Date:  1991       Impact factor: 2.984

4.  Activator protein deficient Gaucher's disease. A second patient with the newly identified lipid storage disorder.

Authors:  H Christomanou; A Chabás; T Pámpols; A Guardiola
Journal:  Klin Wochenschr       Date:  1989-10-02

5.  The precursor of sulfatide activator protein is processed to three different proteins.

Authors:  W Fürst; W Machleidt; K Sandhoff
Journal:  Biol Chem Hoppe Seyler       Date:  1988-05

6.  Two dimensional then layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots.

Authors:  G Rouser; S Fkeischer; A Yamamoto
Journal:  Lipids       Date:  1970-05       Impact factor: 1.880

7.  Human acid beta-glucosidase. Use of inhibitory and activating monoclonal antibodies to investigate the enzyme's catalytic mechanism and saposin A and C binding sites.

Authors:  D Fabbro; G A Grabowski
Journal:  J Biol Chem       Date:  1991-08-15       Impact factor: 5.157

8.  Interaction of saposins, acidic lipids, and glucosylceramidase.

Authors:  S Morimoto; Y Kishimoto; J Tomich; S Weiler; T Ohashi; J A Barranger; K A Kretz; J S O'Brien
Journal:  J Biol Chem       Date:  1990-02-05       Impact factor: 5.157

9.  Simultaneous deficiency of sphingolipid activator proteins 1 and 2 is caused by a mutation in the initiation codon of their common gene.

Authors:  D Schnabel; M Schröder; W Fürst; A Klein; R Hurwitz; T Zenk; J Weber; K Harzer; B C Paton; A Poulos
Journal:  J Biol Chem       Date:  1992-02-15       Impact factor: 5.157

10.  Studies on a sphingolipid activator protein (SAP-2) in fibroblasts from patients with lysosomal storage diseases, including Niemann-Pick disease Type C.

Authors:  S Fujibayashi; D A Wenger
Journal:  Clin Chim Acta       Date:  1985-03-15       Impact factor: 3.786

View more
  28 in total

Review 1.  The protective role of prosaposin and its receptors in the nervous system.

Authors:  Rebecca C Meyer; Michelle M Giddens; Brilee M Coleman; Randy A Hall
Journal:  Brain Res       Date:  2014-08-15       Impact factor: 3.252

2.  Ceramide accumulation is associated with increased apoptotic cell death in cultured fibroblasts of sphingolipid activator protein-deficient mouse but not in fibroblasts of patients with Farber disease.

Authors:  J Tohyama; Y Oya; T Ezoe; M T Vanier; H Nakayasu; N Fujita; K Suzuki
Journal:  J Inherit Metab Dis       Date:  1999-06       Impact factor: 4.982

3.  Leptomeningeal lipid storage patterns in Fabry disease.

Authors:  M Elleder; H Christomanou; B Kustermann-Kuhn; K Harzer
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

Review 4.  Glycosphingolipid degradation and animal models of GM2-gangliosidoses.

Authors:  T Kolter; K Sandhoff
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

Review 5.  Animal models of lysosomal disease: an overview.

Authors:  K Suzuki; J E Månsson
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

6.  Cellular uptake of saposin (SAP) precursor and lysosomal delivery by the low density lipoprotein receptor-related protein (LRP).

Authors:  T Hiesberger; S Hüttler; A Rohlmann; W Schneider; K Sandhoff; J Herz
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

7.  Recombinant GM2-activator protein stimulates in vivo degradation of GA2 in GM2 gangliosidosis AB variant fibroblasts but exhibits no detectable binding of GA2 in an in vitro assay.

Authors:  U Bierfreund; T Lemm; A Hoffmann; G Uhlhorn-Dierks; R A Childs; C T Yuen; T Feizi; K Sandhoff
Journal:  Neurochem Res       Date:  1999-02       Impact factor: 3.996

Review 8.  Saposins and their interaction with lipids.

Authors:  A M Vaccaro; R Salvioli; M Tatti; F Ciaffoni
Journal:  Neurochem Res       Date:  1999-02       Impact factor: 3.996

9.  Neurolysosomal pathology in human prosaposin deficiency suggests essential neurotrophic function of prosaposin.

Authors:  Jakub Sikora; Klaus Harzer; Milan Elleder
Journal:  Acta Neuropathol       Date:  2006-10-06       Impact factor: 17.088

Review 10.  Roles and regulation of secretory and lysosomal acid sphingomyelinase.

Authors:  Russell W Jenkins; Daniel Canals; Yusuf A Hannun
Journal:  Cell Signal       Date:  2009-06       Impact factor: 4.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.